2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Cholangiocarcinoma
10
Acrocephalosyndactylia
6
Carcinoma, Transitional Cell
5
Neoplasm Metastasis
4
Breast Neoplasms
4
Gastrointestinal Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Stomach Neoplasms
2
Solid Tumor
2
Recurrence
2
Pancreatic Neoplasms
2
Neoplasms
2
Myeloproliferative Disorders
2
Lung Neoplasms
2
Endometrial Neoplasms
2
Colorectal Neoplasms
2
Carcinoma
2
Urinary Bladder Neoplasms
1
Solid Tumor, Miscellaneous
1
Sarcoma
1
Oligodendroglioma
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasms, Unknown Primary
1
Multiple Myeloma
1
Lymphoma, Mantle-Cell
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma, B-Cell
1
Locally Advanced Unresectable Gastric Cancer
1
Liposarcoma
1
Leukemia, Myeloid, Acute
1
Interventions
Temozolomide
159
Bevacizumab
69
Radiotherapy
68
Magnetic Resonance Spectroscopy
68
Irinotecan
31
Surgical Procedures, Operative
27
Radiation
24
Carboplatin
23
Specimen Handling
20
Carmustine
20
Blood Specimen Collection
20
Nivolumab
19
Aminolevulinic Acid
18
Biopsy
17
Lomustine
15
pembrolizumab
13
Radiotherapy, Intensity-Modulated
13
Cyclophosphamide
13
trametinib
12
fluorodopa F 18
12
X-Rays
12
Radiosurgery
12
Erlotinib Hydrochloride
12
Topotecan
11
Everolimus
11
Magnetic Resonance Imaging
10
IL13-PE38
10
dabrafenib
9
Etoposide
9
Drug Therapy
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Glioma
×
pemigatinib
×
Clear all
NCT05267106
2025-12-30
FIGHT-209
Incyte Corporation
Phase 2
Terminated
83 enrolled
18 charts